Strong efficacy signals showing 33% ORR, 16.6-month PFS, and 27-month OS, improving on the SOC by 2-3X in a ...

The U.S. FDA has granted fast track status to pelareorep combination therapy for some KRAS-mutant, microsatellite-stable metastatic colorectal cancers.

Strong efficacy signals showing 33% ORR, 16.6-month PFS, and 27-month OS, improving on the SOC by 2-3X in a difficult-to-treat population Company to launch controlled study in second-line KRAS-mutant ...

Last year, nearly 135,000 people in the Netherlands were diagnosed with cancer for the first time. This is almost the same ...

The FDA has granted fast track designation to the investigational oncolytic virus immunotherapy pelareorep (Reolysin) in combination with bevacizumab (Avastin) and FOLFIRI (leucovorin, fluorouracil, ...

Investing.com -- Oncolytics Biotech Inc (NASDAQ:ONCY) stock surged 16.2% Wednesday after the FDA granted Fast Track Designation for its pelareorep therapy in colorectal cancer treatment.

This World Cancer Day, Pfizer Canada ULC ("Pfizer"), in partnership with leading oncology patient organizations, is proud to ...

The agency granted the designation to pelareorep in combination with bevacizumab and leucovorin, fluorouracil, irinotecan for ...

CAEVES Technology, Inc., today announced the general availability of CAEVES Intelligent Deep Storagetm, a software-defined storage platform built natively for Microsoft Azure. CAEVES enables ...

Lumicell, Inc., a leader in developing innovative fluorescence-guided imaging technologies for cancer detection, today announced the appointment of Cheryl R. Blanchard, Ph.D., to its Board of ...

A Wigan dad facing his third round of gruelling cancer treatment in a year is urging people to get tested at the earliest possible opportunity.

ETHealthworld.com brings latest dr reddy 039 s laboratories news, views and updates from all top sources for the Indian Health industry.